Cellphire, Inc.
Dba Cellphire
CAGE Code: 48GV8
NCAGE Code: 48GV8
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 614153570
Summary
Cellphire, Inc., Dba Cellphire is an Active Commercial Supplier with the Cage Code 48GV8 and is tracked by Dun & Bradstreet under DUNS Number 614153570..
Address
9430 Key West Ave Ste 219
Rockville MD 20850-3324
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
Dansources Technical Services, Inc. Linda Fang Ht Medical Systems Inc Stream Intl Inc Air Services Inc Lcg Inc Social And Health Services Ltd S.S. Papadopulos & Associates, Inc. Twinbrook Tv And Computer Covington Sharon N Dictaphone Corp Sgl Industries Inc Selecter Div Polytronic Research Inc White Flint Pharmacy Inc Copy Supply Llc Wardwell Richard E Inc Tec Inc Sporicidin International Computer Pros Inc Dally James
Frequently Asked Questions (FAQ) for CAGE 48GV8
- What is CAGE Code 48GV8?
- 48GV8 is the unique identifier used by NATO Organizations to reference the physical entity known as Cellphire, Inc. Dba Cellphire located at 9430 Key West Ave Ste 219, Rockville MD 20850-3324, United States.
- Who is CAGE Code 48GV8?
- 48GV8 refers to Cellphire, Inc. Dba Cellphire located at 9430 Key West Ave Ste 219, Rockville MD 20850-3324, United States.
- Where is CAGE Code 48GV8 Located?
- CAGE Code 48GV8 is located in Rockville, MD, USA.
Contracting History for CAGE 48GV8 Most Recent 25 Records
- W81XWH20C0030
- Cryopreserved Platelets Phase Ii Clinical Trial
- 2 Apr 2021
- Cryopreserved Platelets Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $12,396,022.84
- Department Of Defense (Dod)
- W81XWH20C0030
- Cryopreserved Platelets Phase Ii Clinical Trial
- 17 Jun 2020
- Cryopreserved Platelets Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $7,483,316.95
- Department Of Defense (Dod)
- W81XWH20C0030
- Phase Ii Clinical Trial
- 28 Sep 2021
- Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $12,396,022.84
- Department Of Defense (Dod)
- W81XWH20C0030
- Cryopreserved Platelet (Cpp) Development For Us Fda Licensure
- 19 Dec 2019
- Cryopreserved Platelet (Cpp) Development For Us Fda Licensure
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,683,316.95
- Department Of Defense (Dod)
- W81XWH20C0030
- Phase Ii Clinical Trial
- 26 Apr 2023
- Phase Ii Clinical Trial
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $20,984,848.05
- Department Of Defense (Dod)
- W81XWH20C0030
- Clinical And Regulatory Management In Direct Support Of Eventual Fda Approval Of A Cryopreserved Platelet (Cpp) Product Via The Performance Of Good Clinical Practices (Gcp) Compliant Phase 2 And 3 Clinical Trials.
- 6 Jan 2022
- Clinical And Regulatory Management In Direct Support Of Eventual Fda Approval Of A Cryopreserved Platelet (Cpp) Product Via The Performance Of Good Clinical Practices (Gcp) Compliant Phase 2 And 3 Clinical Trials.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $12,396,022.84
- Department Of Defense (Dod)
- W81XWH20C0030
- Phase Ii Clinical Trial
- 28 Feb 2020
- Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,683,316.95
- Department Of Defense (Dod)
- W81XWH20C0030
- Cryopreserved Platelets Phase Ii Clinical Trial
- 26 Jan 2021
- Cryopreserved Platelets Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $12,396,022.84
- Department Of Defense (Dod)
- W81XWH20C0030
- Cryopreserved Platelets Phase Ii Clinical Trial
- 2 Aug 2022
- Cryopreserved Platelets Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $15,951,958.58
- Department Of Defense (Dod)
- W81XWH20C0030
- Phase Ii Clinical Trial Incremental Fund Clin 0001 Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022.
- 22 Dec 2022
- Phase Ii Clinical Trial Incremental Fund Clin 0001 Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $16,159,599.60
- Department Of Defense (Dod)
- W81XWH20C0030
- Cryopreserved Platelets Phase Ii Clinical Trial
- 15 May 2020
- Cryopreserved Platelets Phase Ii Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $7,483,316.95
- Department Of Defense (Dod)
- W911NF18C0087
- Nce Mod
- 23 Oct 2020
- Nce Mod
- W6qk Acc-Apg Durham
- Department Of Defense (Dod)
- $998,717.00
- Department Of Defense (Dod)
- W911NF20C0051
- Lyophilized Canine Plasma Sequential Phase Ii
- 29 Sep 2020
- Lyophilized Canine Plasma Sequential Phase Ii
- W6qk Acc-Apg Durham
- Department Of Defense (Dod)
- $472,571.33
- Department Of Defense (Dod)
- W911NF20C0051
- First Monthly Technical Report--
- 12 Jul 2021
- First Monthly Technical Report--
- W6qk Acc-Apg Durham
- Department Of Defense (Dod)
- $472,571.33
- Department Of Defense (Dod)
- W911NF20C0051
- Admin Mod To Change Cor And Add Technical Poc
- 16 Nov 2020
- Admin Mod To Change Cor And Add Technical Poc
- W6qk Acc-Apg Durham
- Department Of Defense (Dod)
- $1,103,403.85
- Department Of Defense (Dod)
- HHSO100201300021C
- The Purpose Of This Modification Is To Exercise Option 3 Of The Contract, Add An Updated Hhsr Clause, And Change The Statement Of Work.
- 13 Apr 2020
- The Purpose Of This Modification Is To Exercise Option 3 Of The Contract, Add An Updated Hhsr Clause, And Change The Statement Of Work.
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $82,599,888.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Administrative Modification Is To: 1) Approve A No-Cost Extension To The Period Of Performance Of Option Period 3 To March 31, 2023, To December 31, 2023. 2) Update The Statement Of Work. 3) Allow Use Of Near Expiry And Reject
- 20 Mar 2023
- The Purpose Of This Administrative Modification Is To: 1) Approve A No-Cost Extension To The Period Of Performance Of Option Period 3 To March 31, 2023, To December 31, 2023. 2) Update The Statement Of Work. 3) Allow Use Of Near Expiry And Reject
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $86,099,888.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Modification Is For Additional Funding For Option 2, Complete The Phase I Clinical Study, Extend The Period Of Performance To January 31, 2020 As Well As Update The Statement Of Work (See Attached).
- 16 Jul 2019
- The Purpose Of This Modification Is For Additional Funding For Option 2, Complete The Phase I Clinical Study, Extend The Period Of Performance To January 31, 2020 As Well As Update The Statement Of Work (See Attached).
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $47,974,842.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- Igf::Ot::Igf For Other Functions Cellphire
- 6 Dec 2018
- Igf::Ot::Igf For Other Functions Cellphire
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $45,197,625.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Modification Is To Extend The Period Of Performance Of Option 2 Of The Contract From 06/30/2019 Through 07/31/2019 Without Additional Cost To The Government.
- 30 Jun 2019
- The Purpose Of This Modification Is To Extend The Period Of Performance Of Option 2 Of The Contract From 06/30/2019 Through 07/31/2019 Without Additional Cost To The Government.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $45,197,625.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Administrative Modification Is To: 1) Extend The Service Date Of The Contract To 03/31/2023, Which Will Allow Invoices To Be Paid Successfully.
- 13 Sep 2022
- The Purpose Of This Administrative Modification Is To: 1) Extend The Service Date Of The Contract To 03/31/2023, Which Will Allow Invoices To Be Paid Successfully.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $86,099,888.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Modification Is To Extend The Period Of Performance To End On April 30, 2020 And To Add $1,290,408 To Option 2 Of The Contract.
- 18 Feb 2020
- The Purpose Of This Modification Is To Extend The Period Of Performance To End On April 30, 2020 And To Add $1,290,408 To Option 2 Of The Contract.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $49,265,250.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- Igf::Ot::Igf For Other Functions Cellphire
- 10 Apr 2018
- Igf::Ot::Igf For Other Functions Cellphire
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $45,197,625.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Modification Is To Extend The Period Of Performance To End On March 31, 2020
- 10 Jan 2020
- The Purpose Of This Modification Is To Extend The Period Of Performance To End On March 31, 2020
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $47,974,842.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300021C
- The Purpose Of This Modification Is To Modify Articles G.1 Contracting Officer; And G.2. Contracting Officer Representative Of The Contract Terms.
- 9 Jun 2021
- The Purpose Of This Modification Is To Modify Articles G.1 Contracting Officer; And G.2. Contracting Officer Representative Of The Contract Terms.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $82,599,888.00
- Department Of Health And Human Services (Hhs)